Výsledky vyhledávání - "F E, Millard"

Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized Hodgkin disease and unfavorable prognostic features: A phase II Cancer and Leukemia Group B Study (9051)

Autor: T H, Wasserman, G R, Petroni, F E, Millard, C T, Chung, M, Barcos, J L, Johnson, G P, Canellos, B A, Peterson

Publikováno v: Cancer. 86(8)

The aim of this study was to evaluate a regimen of sequential chemotherapy and radiotherapy for patients with Hodgkin disease.The Cancer and Leukemia Group B conducted a Phase II study of three cycles of etoposide, vinblastine, and doxorubicin (EVA)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::6e34c043d2e118faf6aaeed9117f1ef3
https://pubmed.ncbi.nlm.nih.gov/10526290

Zobrazit plný text záznamu

Granulocyte colony-stimulating factor versus placebo in addition to penicillin G in a randomized blinded study of gram-negative pneumonia sepsis: analysis of survival and multisystem organ failure

Autor: W S, Smith, G E, Sumnicht, R W, Sharpe, D, Samuelson, F E, Millard

Publikováno v: Blood. 86(4)

Sepsis is a common cause of morbidity and mortality. Neutrophils are the major defense against bacterial invasion, and granulocyte colony-stimulating factor (G-CSF) augments both neutrophil number and function. In our study, 160 rabbits were inoculat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b30bb449e281691703670d579c70a8f1
https://pubmed.ncbi.nlm.nih.gov/7543303

Zobrazit plný text záznamu

Phase I study of transgenic B lymphocyte immunization (TLI) against telomerase in androgen-independent prostate cancer (PC)

Autor: M. Zanetti, M. Gerloni, F. E. Millard, D. Darrah, P. Farness

Publikováno v: Journal of Clinical Oncology. 22:2519-2519

2519 Background: Human telomerase reverse transcriptase (hTRT) is expressed in the majority of human tumor cells (>90% of PC) but is absent from most normal adult cells, identifying it as a potential immunotherapeutic target (PNAS 97:4796, 2000). We

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::19b20fad4a4224e10d31cba994071c3f
https://doi.org/10.1200/jco.2004.22.90140.2519

Zobrazit plný text záznamu

A specific assay for anti-HLA antibodies: application to platelet donor selection

Autor: F E, Millard, P, Tani, R, McMillan

Publikováno v: Blood. 70(5)

Alloimmunization to donor class I HLA antigens represents a major obstacle to successful platelet transfusion therapy. It is desirable to distinguish alloimmunization from nonimmunologic causes of poor platelet survival to assess the need for HLA-mat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::359b8bc744ec59137b5af66b1ef9da5f
https://pubmed.ncbi.nlm.nih.gov/3311206

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání